Department of Hematology and Medical Oncology, Hospital Clínico Universitario, Avd. Blasco Ibáñez 17, 46010 Valencia, Spain.
Leuk Res. 2012 Feb;36(2):174-81. doi: 10.1016/j.leukres.2011.06.011. Epub 2011 Jul 2.
The function of the natural modulators of BCR-ABL-induced signaling pathways could influence the results to imatinib treatment. We assessed the association between single nucleotide polymorphisms (SNPs) on genes of the phosphatase family and the suppressors of cytokine signaling and the response to imatinib in 105 patients newly diagnosed with chronic-phase CML. SNPs in SOCS1 (rs243327) and PTPN22 (rs2476601) genes correlated with the risk of primary resistance to imatinib. A high-risk Sokal score, the T allele in PTPN22 SNP, and each copy of the C allele in SOCS1 SNP were adverse prognostic factors for failure-free survival (FFS). Based on such parameters, three risk groups were identified, with the 5-year FFS for each group being 95%, 75%, and 50%, respectively (P<0.001). A simple predictive model including Sokal score and genotype of SOCS1 and PTPN22 SNPs may be useful in the selection of the initial treatment in CML.
BCR-ABL 诱导信号通路的天然调节剂的功能可能会影响伊马替尼治疗的效果。我们评估了磷酸酶家族和细胞因子信号转导抑制因子基因上的单核苷酸多态性（SNP）与 105 例新诊断的慢性期 CML 患者对伊马替尼反应之间的关系。SOCS1（rs243327）和 PTPN22（rs2476601）基因中的 SNP 与伊马替尼原发性耐药的风险相关。高风险的 Sokal 评分、PTPN22 SNP 的 T 等位基因以及 SOCS1 SNP 的每个 C 等位基因拷贝都是无失败生存（FFS）的不良预后因素。基于这些参数，确定了三个风险组，每组的 5 年 FFS 分别为 95%、75%和 50%（P<0.001）。包含 Sokal 评分和 SOCS1 和 PTPN22 SNP 基因型的简单预测模型可能有助于 CML 初始治疗的选择。
